Reuptake blockade is the most common mechanism in psychiatric pharmacology. The strategy is simple: block the transporter that normally recycles a neurotransmitter from the synapse back into the presynaptic terminal, and the neurotransmitter stays in the synapse longer, with more time to bind receptors and produce postsynaptic effects.
Different reuptake blockers target different transporters, and the selectivity profile defines the drug class.
Selective serotonin reuptake inhibitors (SSRIs) — fluoxetine, sertraline, paroxetine, citalopram, escitalopram, fluvoxamine — block the serotonin transporter (SERT) selectively. Synaptic serotonin rises within hours. The clinical antidepressant effect, however, takes four to six weeks because the downstream plasticity changes (autoreceptor desensitization, hippocampal neurogenesis, network remodeling) take time. SSRIs are used for depression, anxiety disorders, OCD, PTSD, PMDD, and panic disorder.
Serotonin-norepinephrine reuptake inhibitors (SNRIs) — venlafaxine, desvenlafaxine, duloxetine, levomilnacipran — block both SERT and the norepinephrine transporter (NET). The dual mechanism is thought to provide additional therapeutic activity through noradrenergic effects, particularly for energy, focus, and pain. Duloxetine is FDA-approved for diabetic peripheral neuropathic pain and fibromyalgia in addition to depression.
Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI). It blocks NET and (more weakly) the dopamine transporter (DAT). Its lack of serotonergic effect distinguishes it from SSRIs and SNRIs — it does not cause sexual side effects, GI side effects, or weight gain in the way serotonergic agents often do. It is used for depression and as a smoking cessation aid (Zyban).
Atomoxetine is a selective norepinephrine reuptake inhibitor (NRI). It is used for ADHD as a non-stimulant alternative to amphetamines and methylphenidate. It has slower onset (weeks rather than hours) and a less robust effect on attention, but it is non-controlled and does not have abuse potential.
Cocaine is the prototype non-selective monoamine reuptake inhibitor. It blocks DAT, NET, and SERT all at once. This non-selective action is part of why cocaine produces such a complex psychoactive profile — stimulant effects from DAT blockade in the nucleus accumbens and PFC, sympathetic activation from NET blockade peripherally, and mood-affecting effects from SERT blockade. The rapid onset of action when smoked or insufflated produces the powerful reinforcement that drives addiction.
Tricyclic antidepressants (TCAs) — amitriptyline, nortriptyline, imipramine, clomipramine — work through reuptake blockade plus a constellation of other receptor effects. They block SERT and NET (their therapeutic mechanism) but also block H1, M1, and alpha-1 receptors (their side effect profile: sedation, anticholinergic effects, orthostatic hypotension). They are highly effective antidepressants but largely supplanted by SSRIs because of side effects and lethality in overdose.
Hold the strategy. Step 4 of the synaptic cycle is reuptake. Block the transporter, prolong the synaptic signal. The selectivity of the blockade determines the drug class.